Meredith A Morgan

 Meredith A. Morgan
Theodore S Lawrence M.D., Ph.D. and Patricia Krause Research Professor of Radiation Oncology
Associate Chair, Department of Radiation and Cancer Biology, Department of Radiation Oncology
Professor of Radiation Oncology, Medical School
Office:
University of Michigan Medical School
Radiation Oncology
1301 Catherine Street
Ann Arbor, Michigan 48109 SPC 5637
Email:
[email protected]
Phone:
Available to mentor
Meredith A Morgan
Meredith A. Morgan
Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Dr. Morgan leads a laboratory focused on improving standard radiation and chemoradiation therapies through the use of novel agents targeting DNA damage response and repair. Her research program prioritizes pre-clinical research with strong clinical/translational relevance with an emphasis on pancreatic cancer. More specific areas of research interest include DNA double-strand break repair, DNA replication, cell cycle and biomarker development.

    Qualifications
    • Research Fellow
      University of Michigan, United States
      2002 - 2005
    • Postdoctoral Research Fellow
      West Virginia University, United States
      2002 - 2002

    Center Memberships
    • Center Member
      Rogel Cancer Center

    Research Overview

    DNA damage response inhibitors
    Radio - and chemo- sensitization
    DNA repair and DNA replication stress
    Immunotherapy and tumor immunology
    Translational research
    Pancreatic cancer and diffuse intrinsic pontine glioma

    Recent Publications

     See All Publications
    • Journal Article
      Microenvironment-derived acetylated amino acids promote glioblastoma treatment resistance.
      Sravya P, Altay LN, Do K, Freeman J, Gokul A, Liang N, Scott AJ, Xu J, Korimerla N, Lin A, Wang H, Wilder-Romans K, Singer A, O'Brien A, Animasahun O, Meghdadi B, Baker E, Peterson ER, McCulla EC, Zhu Z, Thomas D, Andren A, Wong H, Sajjakulnukit P, Zhang L, Shankar S, Ravikumar V, Lee ZH, Carrion JAN, Bhadury S, Miller CR, Sarkaria JN, Heth JA, Huse JT, Camelo-Piragua S, Morgan MA, Lawrence TS, Rao A, Lyssiotis C, Al-Holou W, Nagrath D, Zhou W, Wahl DR. Res Sq, 2026 Sep 18; DOI:10.21203/rs.3.rs-10976328/v1
      PMID: PMC13596666
    • Journal Article
      CRISPR-Cas9 screen identifies eIF4G2 as a regulator of CD8+ T cell dysfunction
      Holcomb EA, Jiang L, Pearson AN, James J, Tate A, Wang A, Dasgupta A, Clauwaert J, Armas ND, Elaimy AL, Palagama DS, Goodwin SK, Kwiatkowski MH, Morgan MA, Courtney AH, Gijón M, Carty SA, Huber AK, Zou W, Prensner JR, Green MD. Journal of Immunology, 2026 Sep 22;
    • Journal Article
      H3K27M enhances basal ATM signaling but is not required for radiosensitization of diffuse midline glioma via ATM inhibition with AZD1390.
      Peterson ER, Parsels LA, Li Z, Zhao X, Hess LD, Guo Y, Messinger D, Parsels JD, Wang Z, Qin T, Valvo VM, Franson AT, Castro MG, Yadav VN, Lawrence TS, Koschmann C, Zhang Q, Wahl DR, Morgan MA. Mol Cancer Ther, 2026 Jul 14; DOI:10.1158/1535-7163.MCT-24-1019
      PMID: 42444560
    • Journal Article
      Liver Metastases License Neutrophils through IL1 to Potentiate Cancer Progression
      Pearson AN, Waninger J, Huber AK, Holcomb EA, James JG, Kyi J, Elaimy AL, Wang Z, Lasse-Opsahl EL, SenGupta S, Elliott DA, Choi E, Zhang Q, Morgan MA, Chang DT, Lawrence TS, Courtney A, Shah YM, Knight JS, Di Magliano MP, Yoo S, Crivelli S, Parent CA, Ramnath N, Bryant AK, Zou W, Green MD. Cancer Immunology Research, 2025 Dec 1; 13 (12): 2023 - 2036. DOI:10.1158/2326-6066.CIR-24-1074
      PMID: 40906822
    • Preprint
      Adaptive nuclear GTP synthesis promotes glioblastoma treatment resistance and is a targetable vulnerability in patients.
      Scott AJ, Liang N, Al-Holou WN, Xu J, O'Brien A, Lin A, Pareek V, Sha Z, Zhao Z, Yang JZ, Yang A, Kothari AU, Wilder-Romans K, Wu Z, Feng J, Korimerla N, Elaimy A, Palavalasa S, Chen J, Wang L, Zhang L, Andren AC, Sajjakulnukit P, Marini B, Heth JA, Morgan MA, Lawrence TS, Benkovic SJ, Nagrath D, Chandrasekaran S, Qi NR, Sun D, Wen B, Pai MP, Clarke N, Suresh K, Umemura Y, Lyssiotis CA, Zhou W, Wahl DR. 2025 Nov 13; DOI:10.1101/2025.11.11.25340023
      PMID: 41292630
    • Journal Article
      H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition
      Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, The S, Hu N, Valvo VM, Doherty R, Peterson E, Wang X, Venkataraman S, Agnihotri S, Wahl DR, Green MD, Lawrence TS, Koschmann C, Morgan MA, Zhang Q. Neuro-Oncology, 2025 Feb 7;
    • Journal Article
      DMG-02. Targeting B7-H3 in combination with radiation against diffuse midline glioma
      Li Z, Guo Y, Wang Z, Parsels L, Parsels J, Wahl D, Lawrence T, Venneti S, Koschmann C, St. Croix B, Morgan M, Zhang Q. Neuro-Oncology Pediatrics, 2026 Apr 24; 1 (Supplement_1): DOI:10.1093/neuped/wuaf001.033
    • Journal Article
      HGG-03. ATRX loss drives epigenetic dysregulation of p16 in pediatric high-grade glioma
      Messinger D, Patel J, Doherty R, Kuchinski K, Clausen M, Momen F, Schwark K, de la Nava Martin D, Parsels LA, Parsels JD, Ji S, Mota M, Venneti S, Zhang Q, Morgan M, Qin T, Yadav VN, Koschmann C. Neuro-Oncology Pediatrics, 2026 Apr 24; 1 (Supplement_1): DOI:10.1093/neuped/wuaf001.139

    Featured News & Stories

         An image of a Linear Accelerator (LINAC)
    Illuminate

    Refining Radiation

    In 2023, a team of Rogel Cancer Center researchers landed one of these high-profile grants around a different theme. Their project centers around radiosensitization: how do specific drugs make radiation more effective in locally advanced pancreas, brain and breast cancers? Dr. Meredith Morgan, co-principle investigator explains.